We are live on
!
Find out more
MFM
MHR Fund Management Portfolio holdings
AUM
$1.37B
1-Year Est. Return
68.35%
This Fund
S&P 500
This Quarter
Est. Return
+22.64%
1 Year Est. Return
+68.35%
3 Year Est. Return
+194.55%
5 Year Est. Return
+128.05%
10 Year Est. Return
+308.92%
AUM
$1.03B
AUM Growth
+$120M
(+13%)
Cap. Flow
+$46.6M
Cap. Flow
% of AUM
4.5%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$46.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.42% |
| 2 | Communication Services | 33.72% |
| 3 | Technology | 14.85% |
| 4 | Industrials | 9.64% |
| 5 | Financials | 7.38% |
Similar funds
ICM
SOS
EFG
PP
RI
HPC
AF
KRS
MHR Fund Management's Q1 2024 Portfolio in Review
As of Q1 2024, MHR Fund Management held 10 positions worth $1.03B, up 13% from $915M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MHR Fund Management deployed $46.6M of net new capital in Q1 2024, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 18% a quarter earlier, followed by Communication Services and Technology.
- MHR Fund Management added most to Iovance Biotherapeutics in Q1 2024, an estimated $46.6M increase.
- MHR Fund Management's ten largest holdings make up 100% of its $1.03B portfolio in Q1 2024.
- MHR Fund Management opened 0 new positions and closed 0 in Q1 2024.
- MHR Fund Management's portfolio value rose 13% quarter-over-quarter to $1.03B.
Based on MHR Fund Management's 13F filing for Q1 2024, filed 15 May 2024.